Publications by authors named "Robin Dore"

Claim this Profile
A
Associations of Cost Sharing With Rheumatoid Arthritis Disease Burden.
Sharon Dowell, Christopher J Swearingen, Manuela Pedra-Nobre, Dianne Wollaston, Sawsan Najmey, Robin Dore

ACR Open Rheumatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States.
Sharon Dowell, Huifeng Yun, Jeffrey R Curtis, Lang Chen, Fenglong Xie, Robin Dore

ACR Open Rheumatol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States.
Robin K Dore, Jenya N Antonova, Chakkarin Burudpakdee, Lawrence Chang, Magdaliz Gorritz

ACR Open Rheumatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.
Kenneth G Saag, Michele T McDermott, Jonathan Adachi, Willem Lems, Nancy E Lane, Robin Dore

Arthritis Rheumatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
Benjamin Z Leder, Carol Zapalowski, Ming-Yi Hu, Gary Hattersley, Nancy E Lane, Robin K Dore

J Bone Miner Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Robin K Dore

J Clin Endocrinol Metab· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Comment on the Article by Buckley et al.
Michael Maricic, Chad Deal, Robin Dore, Andrew Laster

Arthritis Care Res (Hoboken)· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of etanercept in the treatment of arthritides in children and adolescents.
Robin K Dore

Adolesc Health Med Ther· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should healthy people take calcium and vitamin D to prevent fractures? What the US Preventive Services Task Force and others say.
Robin K Dore

Cleve Clin J Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.
Robin K Dore

Patient Prefer Adherence· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data from extension trials: denosumab and zoledronic acid.
Robin K Dore

Curr Osteoporos Rep· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The RANKL pathway and denosumab.
Robin K Dore

Rheum Dis Clin North Am· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to prevent glucocorticoid-induced osteoporosis.
Robin K Dore

Cleve Clin J Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.
Robin K Dore, Stanley B Cohen, Nancy E Lane, William Palmer, William Shergy

Ann Rheum Dis· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient experience with a new teriparatide delivery device.
Robin K Dore, Robert G Feldman, Kathleen A Taylor, Kyoungah See, Gail P Dalsky

Curr Med Res Opin· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gout: what primary care physicians want to know.
Robin K Dore

J Clin Rheumatol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The gout diagnosis.
Robin K Dore

Cleve Clin J Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Stanley B Cohen, Robin K Dore, Nancy E Lane, Peter A Ory, Charles G Peterfy

Arthritis Rheum· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced risk of back pain following teriparatide treatment: a meta-analysis.
Michael C Nevitt, Peiqi Chen, Robin K Dore, Jean-Yves Reginster, Douglas P Kiel

Osteoporos Int· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
John Tesser, Roy Fleischmann, Robin Dore, Ralph Bennett, Alan Solinger

J Rheumatol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteoporosis in the elderly: a clinical perspective of current and future therapies.
Robin K Dore, Daniel J Hurley

J Am Med Dir Assoc· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Jean-Jacques Body, Gregory A Gaich, Wim H Scheele, Pandurang M Kulkarni, Paul D Miller, Robin K Dore

J Clin Endocrinol Metab· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
Rose S Fife, Walter F Chase, Robin K Dore, Craig W Wiesenhutter, Peter B Lockhart

Arch Intern Med· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis